Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 12:13:a25097671.
doi: 10.1055/a-2509-7671. eCollection 2025.

Endoscopic ultrasound gastroenterostomy vs duodenal stenting for malignant gastric outlet obstruction: Cost-effectiveness study

Affiliations

Endoscopic ultrasound gastroenterostomy vs duodenal stenting for malignant gastric outlet obstruction: Cost-effectiveness study

Daryl Ramai et al. Endosc Int Open. .

Abstract

Background and study aims: Enteral stenting has been traditionally employed for managing malignant gastric outlet obstruction (GOO). However, concerns regarding high reintervention rates have brought into question its cost-effectiveness. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) with a lumen-apposing metal stent (LAMS) provides an alternative to luminal stenting. The goal of this study was to assess the cost-effectiveness of EUS-GE relative to duodenal stenting.

Patients and methods: A decision analysis was performed to analyze costs and survival in patients with unresectable or metastatic GOO. The model was designed with two treatment arms: self-expanding metal stent (SEMS) placement and EUS-GE with LAMS. Costs were derived from Medicare reimbursement rates (US$) while effectiveness was measured by quality-adjusted life years (QALYs). The primary outcome measure was the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analyses were performed.

Results: Endoscopic stenting resulted in an average cost of $22,748 and 0.31 QALYs whereas EUS-GE cost $32,254 and yielded 0.53 QALYs, which yielded a difference of $9,507 in cost and 0.23 in QALY. EUS-GE was found to be a cost-effective strategy over duodenal stenting (ICER, $41994/QALY) at a willingness-to-pay of $100,000/QALY. In 10,000 Monte-Carlo simulations, EUS-GE was favored 62% of the time. Using a tornado diagram, the model was most sensitive to the probability of mortality in patients with duodenal stents compared with EUS-GE.

Conclusions: In patients with malignant GOO, EUS-GE is a cost-effective palliative intervention compared with duodenal stenting.

Keywords: Endoscopic ultrasonography; Endoscopy Lower GI Tract; Endoscopy Upper GI Tract; Stenting.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Decision tree. Shown is the simulation model used to estimate costs, clinical outcomes, and quality-adjusted life-years of patients undergoing duodenal stenting or EUS-GE for malignant gastric outlet obstruction (GOO). a Duodenal stenting and EUS-GE and the health states of the patients. b Three categories of subsequent clinical events: mortality at 1 month, survival, stent patency, and stent failure. The blue square indicates the decision node, the point at which a treatment strategy is chosen; the blue encircled letter “M” indicates the Markov node, with branches indicating the health states in transition every 1 month; the green circle indicates the chance node, after which there is a probability of the occurrence of each event; and the red triangle indicates the terminal node, the end of a pathway within a 12-month cycle.
Fig. 2
Fig. 2
Tornado diagram showing the model is sensitive to the probability of mortality in patients with duodenal stents and failure of duodenal stents compared with endoscopic ultrasound gastroenterostomy (EUS-GE). WTP, willingness to pay; ICER, incremental cost-effectiveness ratio.
Fig. 3
Fig. 3
Scatter plot of probabilistic sensitivity analysis. The incremental cost-effectiveness scatter plot for each of the two studied treatment strategies showing the iterations occurring either above (duodenal stenting) or below (EUS-GE) the willingness-to-pay (WTP) threshold of $100,000/quality-adjusted life-year (QALY), with the oval showing the 95% confidence interval. This visually represents what was found in the cost-effectiveness acceptability curve.

References

    1. Sánchez-Aldehuelo R, Iñigo JC, Moreno BM et al.EUS-guided gastroenterostomy versus duodenal self-expandable metal stent for malignant gastric outlet obstruction: results from a nationwide multicenter retrospective study (with video) Gastrointest Endosc. 2022;96:1012–1020. - PubMed
    1. Miller C, Benchaya JA, Martel M et al.EUS-guided gastroenterostomy vs. surgical gastrojejunostomy and enteral stenting for malignant gastric outlet obstruction: a meta-analysis. Endosc Inter Open. 2023;1:E660–E6672. doi: 10.1055/a-2098-2570. - DOI - PMC - PubMed
    1. Vanella G, Dell’Anna G, Capurso G et al.EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective cohort study with matched comparison with enteral stenting. Gastrointest Endosc. 2023;98:337–347. - PubMed
    1. Teoh AYB, Lakhtakia S, Tarantino I et al.Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:124–132. doi: 10.1016/S2468-1253(23)00242-X. - DOI - PubMed
    1. Ramai D, Facciorusso A, Crinò SF et al.EUS-guided gastroenteric anastomosis: A first-line approach for gastric outlet obstruction? Endosc Ultrasound. 2021;10:404–405. doi: 10.4103/EUS-D-21-00238. - DOI - PMC - PubMed

LinkOut - more resources